Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1939)	10/4/2007 4:01:57 PM
From: Jibacoa	Respond to of 3722

SLXP Didn't close completely its Sep 6 UG. bigcharts.marketwatch.com The UG & spike that day, on volume of 9,882,400 was after it announced the results of the first of 2 PIIIs of its new granulated mesalamine product for patients with ulcerative colitis. The results showed a statistically significant proportion of subjects dosed with 1.5gms/day of granulated mesalamine remained relapse-free for 6 months more than than patients treated with placebo. Today it announced the results of the second PIII of its granulated mesalamine product, which showed statistically significant same results, confirming the results of the previous PIII.<g> They expect to file an NDA in December for this product. SLXP Needs to close above $14 before it can try to test its larger resistance above $15. It has 4Qs of better revenues & the earnings also improved in the last (2nd)Q. The short ratio is around 16x its ADV although it came down some in the last month. bigcharts.marketwatch.com Bernard